1009083-66-2Relevant academic research and scientific papers
P2Y1 receptor antagonists as novel antithrombotic agents
Pfefferkorn, Jeffrey A.,Choi, Chulho,Winters, Thomas,Kennedy, Robert,Chi, Liguo,Perrin, Lisa A.,Lu, Gina,Ping, Yun-Wen,McClanahan, Tom,Schroeder, Richard,Leininger, Michael T.,Geyer, Andrew,Schefzick, Sabine,Atherton, James
body text, p. 3338 - 3343 (2009/04/06)
The P2Y1 and P2Y12 purinergic receptors are responsible for mediating adenosine diphosphate (ADP) dependent platelet aggregation. Evidence from P2Y1 knockout studies as well as from nucleotide-based small molecule P2Y1 antagonists has suggested that the antagonism of this receptor may offer a novel and effective method for the treatment of thrombotic disorders. Herein, we report the identification and optimization of a series of non-nucleotide P2Y1 antagonists that are potent and orally bioavailable.
PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS
-
Page/Page column 44-45, (2010/11/30)
This invention relates to novel compounds of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof wherein Y, R1 through R9, and X1 through X7 are as defined in the specification, pharmaceutical compositions containing said compounds useful as P2Y1 antagonists, and to methods of treating thromboembolic disorders.
